Premium
Dianthus Therapeutics Inc (DNTH)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Mr. Adam M. VenessSenior VP, General Counsel & Secretary | -30,00k | 1,89M | Derivative Exercise and Sale | 17,88 - 81,38 | 0,00 | - |
| 2026-06-01 | Dr. Simrat RandhawaExec. VP and Head of R&D | -26,53k | 1,90M | Derivative Exercise and Sale | 8,44 - 91,37 | 4,00k | - |
| 2026-05-08 | Ms. Paula SoteropoulosIndependent Director | -599,00 | 46,14k | Derivative Exercise and Sale | 8,44 - 85,47 | 0,00 | - |
| 2026-04-09 | Mr. Ryan SavitzExec. VP, CFO, Chief Business Officer & Treasurer | -8,22k | 591,80k | Derivative Exercise and Sale | 17,88 - 89,84 | 0,00 | - |
| 2026-03-31 | Mr. Ryan SavitzExec. VP, CFO, Chief Business Officer & Treasurer | -114,37k | 8,15M | Derivative Exercise and Sale | 8,44 - 85,54 | 0,00 | - |
| 2026-03-31 | Ms. Paula SoteropoulosIndependent Director | -599,00 | 42,93k | Derivative Exercise and Sale | 8,44 - 80,11 | 0,00 | - |
| 2026-03-24 | Ms. Paula SoteropoulosIndependent Director | -27,59k | 1,92M | Derivative Exercise and Sale | 8,44 - 78,05 | 0,00 | - |
| 2026-03-16 | Mr. Marino GarciaPresident, CEO & Director | 65,29k | 499,97k | Derivative Exercise and Retained Stock | 6,70 - 17,88 | 65,29k | - |
| 2026-03-12 | Dr. Simrat RandhawaExec. VP and Head of R&D | -33,83k | 2,14M | Derivative Exercise and Sale | 8,44 - 81,48 | 0,00 | - |
| 2026-03-12 | Mr. Marino GarciaPresident, CEO & Director | -122,92k | 9,19M | Derivative Exercise and Sale | 6,70 - 85,53 | 0,00 | - |
| 2026-03-12 | Mr. Edward G. CarrSenior VP & CAO | -43,68k | 2,67M | Derivative Exercise and Sale | 17,88 - 85,53 | 0,00 | - |
| 2025-12-04 | Mr. Ryan SavitzExec. VP, CFO, Chief Business Officer & Treasurer | -20,00k | 734,80k | Derivative Exercise and Sale | 8,44 - 45,18 | 0,00 | - |
| 2025-11-21 | Fairmount Funds Management LLCSociété | -1,17M | 46,22M | Vente | 39,50 | 2,14M | -35,38% |
| 2025-11-13 | Dr. Simrat RandhawaExec. VP and Head of R&D | -196,54k | 4,38M | Derivative Exercise and Sale | 8,44 - 38,14 | 4,00k | - |
| 2025-09-11 | Fairmount Funds Management LLCSociété | 600,00k | 19,80M | Achat | 33,00 | 3,31M | 22,16% |
| 2025-09-09 | Mr. Ryan SavitzExec. VP, CFO, Chief Business Officer & Treasurer | -20,00k | 531,20k | Derivative Exercise and Sale | 8,44 - 35,00 | 0,00 | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
